Literature DB >> 26607155

[A software tool for pure-tone audiometry: Classification of audiograms for inclusion of patients in clinical trials. German version].

T Rahne1, F Buthut2, S Plößl2, S K Plontke2.   

Abstract

OBJECTIVE: Selecting subjects for clinical trials on hearing loss therapies relies on the patient meeting the audiological inclusion criteria. In studies on the treatment of idiopathic sudden sensorineural hearing loss, the patient's acute audiogram is usually compared with a previous audiogram, the audiogram of the non-affected ear, or a normal audiogram according to an ISO standard. Generally, many more patients are screened than actually fulfill the particular inclusion criteria. The inclusion criteria often require a calculation of pure-tone averages, selection of the most affected frequencies, and calculation of hearing loss differences.
MATERIALS AND METHODS: A software tool was developed to simplify and accelerate this inclusion procedure for investigators to estimate the possible recruitment rate during the planning phase of a clinical trial and during the actual study. This tool is Microsoft Excel-based and easy to modify to meet the particular inclusion criteria of a specific clinical trial. The tool was retrospectively evaluated on 100 patients with acute hearing loss comparing the times for classifying automatically and manually. The study sample comprised 100 patients with idiopathic sudden sensorineural hearing loss. RESULTS AND
CONCLUSION: The age- and sex-related normative audiogram was calculated automatically by the tool and the hearing impairment was graded. The estimated recruitment rate of our sample was quickly calculated. Information about meeting the inclusion criteria was provided instantaneously. A significant reduction of 30% in the time required for classifying (30 s per patient) was observed.

Entities:  

Keywords:  Epidemiologic research design; Health care evaluation mechanisms; Hearing tests; Sensorineural hearing loss; Sudden hearing loss

Mesh:

Year:  2015        PMID: 26607155     DOI: 10.1007/s00106-015-0093-7

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  23 in total

1.  [Intratympanic glucocorticoid therapy of sudden hearing loss].

Authors:  S K Plontke
Journal:  HNO       Date:  2010-10       Impact factor: 1.284

2.  Hemodilution therapy with hydroxyethyl starch solution (130/0.4) in unilateral idiopathic sudden sensorineural hearing loss: a dose-finding, double-blind, placebo-controlled, international multicenter trial with 210 patients.

Authors:  Eckart Klemm; Frank Bepperling; Martin A Burschka; Ralph Mösges
Journal:  Otol Neurotol       Date:  2007-02       Impact factor: 2.311

3.  Comparison of pure-tone audiometry analysis in sudden hearing loss studies: lack of agreement for different outcome measures.

Authors:  Stefan K Plontke; Michael Bauer; Christoph Meisner
Journal:  Otol Neurotol       Date:  2007-09       Impact factor: 2.311

4.  Clinical practice guideline: sudden hearing loss.

Authors:  Robert J Stachler; Sujana S Chandrasekhar; Sanford M Archer; Richard M Rosenfeld; Seth R Schwartz; David M Barrs; Steven R Brown; Terry D Fife; Peg Ford; Theodore G Ganiats; Deena B Hollingsworth; Christopher A Lewandowski; Joseph J Montano; James E Saunders; Debara L Tucci; Michael Valente; Barbara E Warren; Kathleen L Yaremchuk; Peter J Robertson
Journal:  Otolaryngol Head Neck Surg       Date:  2012-03       Impact factor: 3.497

5.  [Levels of normal hearing].

Authors:  O Michel
Journal:  HNO       Date:  2014-09       Impact factor: 1.284

6.  Uses and abuses of hearing loss classification.

Authors:  J G Clark
Journal:  ASHA       Date:  1981-07

7.  Treatment of sudden sensorineural hearing loss with systemic steroids and valacyclovir.

Authors:  Debara L Tucci; Joseph C Farmer; Russell D Kitch; David L Witsell
Journal:  Otol Neurotol       Date:  2002-05       Impact factor: 2.311

8.  [Tympanotomy and sealing of the round window membrane in sudden sensorineural hearing loss: a retrospective analysis].

Authors:  U Reineke; M Hühnerschulte; J Ebmeyer; H Sudhoff
Journal:  HNO       Date:  2013-04       Impact factor: 1.284

9.  Evaluation of prostaglandin E1 therapy for sudden deafness.

Authors:  T Nakashima; K Kuno; N Yanagita
Journal:  Laryngoscope       Date:  1989-05       Impact factor: 3.325

10.  Efficacy and safety of AM-111 in the treatment of acute sensorineural hearing loss: a double-blind, randomized, placebo-controlled phase II study.

Authors:  Markus Suckfuell; Grazyna Lisowska; Wojciech Domka; Anna Kabacinska; Krzysztof Morawski; Robert Bodlaj; Petr Klimak; Rom Kostrica; Thomas Meyer
Journal:  Otol Neurotol       Date:  2014-09       Impact factor: 2.311

View more
  1 in total

1.  [Multicenter trial for sudden hearing loss therapy - planning and concept].

Authors:  S K Plontke; M Girndt; C Meisner; R Probst; I Oerlecke; M Richter; J Steighardt; G Dreier; A Weber; I Baumann; S Plößl; J Löhler; R Laszig; J A Werner; T Rahne
Journal:  HNO       Date:  2016-04       Impact factor: 1.284

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.